aMylla

aMylla is a biotech spin-off pioneering Live Biotherapeutics, medicines made from living bacteria, targeting respiratory and women’s health. We develop our bacteria pharma-style: each well-characterized strain delivers precise, beneficial activities, from immune modulation and epithelial barrier reinforcement to anti-pathogenic effects.

Our mission goes beyond individual health. We aim to contribute to planetary health by offering sustainable alternatives to antibiotics, helping combat antimicrobial resistance. We focus on underserved populations, particularly women and children, where medical needs are highest. From day one, our products are designed with low manufacturing costs to ensure broad accessibility, all while upholding responsible, sustainable production practices.